Neurophysiological effects of a combined treatment of lovastatin and minocycline in patients with fragile X syndrome: Ancillary results of the LOVAMIX randomized clinical trial
Authors:
Open Access
- 9 September 2024
- journal article
- research article
- Published by Wiley in Autism Research
- Vol. 17 (9) , 1944-1956
Abstract
Fragile X syndrome (FXS) is the primary hereditary cause of intellectual disability and autism spectrum disorder. It is characterized by exacerbated neuronal excitability, and its correction is considered an objective measure of treatment response in animal models, a marker albeit rarely used in clinical trials. Here, we used an extensive transcranial magnetic stimulation (TMS) battery to assess the neurophysiological effects of a therapy combining two disease‐modifying drugs, lovastatin (40 mg) and minocycline (100 mg), administered alone for 8 weeks and in combination for 12 weeks, in 19 patients (mean age of 23.58 ± 1.51) with FXS taking part in the LOVAmix trial. The TMS battery, which included the resting motor threshold, short‐interval intracortical inhibition, long‐interval intracortical inhibition, corticospinal silent period, and intracortical facilitation, was completed at baseline after 8 weeks of monotherapy (visit 2 of the clinical trial) and after 12 weeks of dual therapy (visit 4 of the clinical trial). Repeated measure ANOVAs were performed between baseline and visit 2 (monotherapy) and visit 3 (dual therapy) with interactions for which monotherapy the participants received when they began the clinical trial. Results showed that dual therapy was associated with reduced cortical excitability after 20 weeks. This was reflected by a significant increase in the resting‐motor threshold after dual therapy compared to baseline. There was a tendency for enhanced short‐intracortical inhibition, a marker of GABAa‐mediated inhibition after 8 weeks of monotherapy compared to baseline. Together, these results suggest that a combined therapy of minocycline and lovastatin might act on the core neurophysiopathology of FXS. This trial was registered at clinicaltrials.gov (NCT02680379).Keywords
Funding Information
- Fondation du Grand défi Pierre Lavoie
- FRAXA Research Foundation
This publication has 79 references indexed in Scilit:
- The clustering of voltage‐gated sodium channels in various excitable membranesDevelopmental Neurobiology, 2019
- Longitudinal assessment of 1H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortexExperimental Brain Research, 2019
- Rescue of deficient amygdala tonic γ‐aminobutyric acidergic currents in theFmr–/ymouse model of fragile X syndrome by a novel γ‐aminobutyric acid type A receptor‐positive allosteric modulatorJournal of Neuroscience Research, 2015
- Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and BackNeurotherapeutics, 2015
- Effect of lovastatin on behavior in children and adults with fragile X syndrome: An open‐label studyAmerican Journal of Medical Genetics Part A, 2014
- High MMP‐9 activity levels in fragile X syndrome are lowered by minocyclineAmerican Journal of Medical Genetics Part A, 2013
- Effects of minocycline on Na+ currents in rat dorsal root ganglion neuronsBrain Research, 2011
- Structure, function and pharmacology of voltage-gated sodium channelsNaunyn-Schmiedeberg's Archives of Pharmacology, 2000
- Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndromeCell, 1991
- New polymorphism and a new chromosome breakpoint establish the physical and genetic mapping of DXS369 in the DXS98‐FRAXA IntervalAmerican Journal of Medical Genetics, 1991